Dataset Information

Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy.

ABSTRACT:

Background

This study aimed to evaluate the predictive potential of contrast-enhanced computed tomography (CT)-based imaging biomarkers (IBMs) for the treatment outcomes of patients with oesophageal squamous cell carcinoma (OSCC) after definitive concurrent chemoradiotherapy (CCRT).

Methods

Altogether, 154 patients with OSCC who underwent definitive CCRT were included in this retrospective study. All patients were randomised to the training cohort (n?=?99) or the validation cohort (n?=?55). Pre-treatment contrast-enhanced CT scans were obtained for all patients and used for the extraction of IBMs. An IBM score, was constructed by using the least absolute shrinkage and selection operator with Cox regression analysis, which was equal to the log-partial hazard of the Cox model in the training cohort and tested in the validation cohort. IBM nomograms were built based on IBM scores for individualised survival estimation. Finally, a decision curve analysis was performed to estimate the clinical usefulness of the nomograms.

Results

Altogether, 96 IBMs were extracted from each contrast-enhanced CT scan. IBM scores were constructed from 11 CT-based IBMs for overall survival (OS) and 8 IBMs for progression-free survival (PFS), using the LASSO-Cox regression method in the training cohort. Multivariate analysis revealed that IBM score was an independent prognostic factor correlated with OS and PFS. In the training cohort, the C-indices of IBM scores were 0.734 (95% CI 0.664-0.804) and 0.658 (95% CI 0.587-0.729) for OS and PFS, respectively. In the validation cohort, C-indices were 0.672 (95% CI 0.578-0.766) and 0.666 (95% CI 0.574-0.758) for OS and PFS, respectively. Kaplan-Meier survival analysis showed a significant difference between risk subgroups in the training and validation cohorts. Decision curve analysis confirmed the clinical usefulness of the IBM score.

Conclusions

The IBM score based on pre-treatment contrast-enhanced CT could predict the OS and PFS for patients with OSCC after definitive CCRT. Further multicentre studies with larger sample sizes are warranted.

SUBMITTER: Zeng C

PROVIDER: S-EPMC7805131 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy.

Zeng Chengbing C Zhai Tiantian T Chen Jianzhou J Guo Longjia L Huang Baotian B Guo Hong H Liu Guozhi G Zhuang Tingting T Liu Weitong W Luo Ting T Wu Yanxuan Y Peng Guobo G Li Derui D Chen Chuangzhen C

Radiation oncology (London, England) 20210112 1

<h4>Background</h4>This study aimed to evaluate the predictive potential of contrast-enhanced computed tomography (CT)-based imaging biomarkers (IBMs) for the treatment outcomes of patients with oesophageal squamous cell carcinoma (OSCC) after definitive concurrent chemoradiotherapy (CCRT).<h4>Methods</h4>Altogether, 154 patients with OSCC who underwent definitive CCRT were included in this retrospective study. All patients were randomised to the training cohort (n = 99) or the validation cohort ...[more]

PMID: 33436018

Similar Datasets

Project description:In the present study, we aimed to construct a radiomics model using contrast‑enhanced computed tomography (CT) to predict the pathological invasiveness of thymic epithelial tumors (TETs). We retrospectively reviewed the records of 179 consecutive patients (89 females) with histologically confirmed TETs from two hospitals. The 82 low‑ and 97 high‑risk TETs were assigned to training (90 tumors), internal validation (49 tumors) and external validation (40 tumors) cohorts. Radiomics features extracted from preoperative contrast‑enhanced chest CT were selected using least absolute shrinkage and selection operator logistic regression. Three prediction models were developed using multivariate logistic regression analysis. Their performance and clinical utility were assessed using receiver operating characteristic curves and the DeLong test, respectively. Eight radiomics features with non‑zero coefficients were used to develop a radiomics score, which significantly differed between low‑ and high‑risk TETs (P<0.001). The subjective finding, infiltration, was independently associated with high‑risk TETs. Prediction models based on infiltration alone, the radiomics signature alone, and both these parameters showed diagnostic accuracies of 72.2% [area under curve (AUC), 0.731; 95% confidence interval (CI): 0.627‑0.819; sensitivity, 85.7%; specificity, 60.4%], 88.9% (AUC, 0.944; 95% CI: 0.874‑0.981; sensitivity, 92.9%; specificity, 85.4%), and 90.0% (AUC, 0.953; 95% CI: 0.887‑0.987; sensitivity, 92.9%; specificity, 87.5%), respectively. Decision‑curve analysis showed that the combined model added more net benefit than the single‑parameter models. In conclusion, a radiomics signature based on contrast‑enhanced CT has the potential to differentiate between low‑ and high‑risk TETs. The model incorporating the radiomics signature and subjective finding may facilitate the individualized, preoperative prediction of the pathological invasiveness of TETs.

Project description:BACKGROUND:Limited data describe patient-reported outcomes (PROs) of localised oesophageal cancer treated with definitive chemoradiotherapy(CRT). The phase 2/3 SCOPE-1 trial assessed the effectiveness of CRT±cetuximab. The trial for the first time provided an opportunity to describe PROs from a multi-centre group of patients treated with CRT that are presented here. METHODS:Patients undergoing CRT±cetuximab within the SCOPE-1 trial (258 patients from 36 UK centres) completed generic-, disease- and treatment-specific health-related quality of life (HRQL) questionnaires (EORTC QLQ-C30, QLQ-OES18, Dermatology Life-Quality Index (DLQI)) at baseline and at 7, 13, 24, 52 and 104 weeks. Mean EORTC functional scale scores (>15 point change significant), DLQI scores (>4 point change significant) and proportions of patients (>15% significant) with 'minimal' or 'severe' symptoms are presented. RESULTS:Questionnaire response rates were good. At baseline, EORTC functional scores were high (>75%) and few symptoms were reported except for severe problems with fatigue, insomnia and eating-related symptoms (e.g., appetite loss, dysphagia, dry mouth) in both groups(>15%). Functional aspects of health deteriorated and symptoms increased with treatment and by week 13 global quality of life, physical, role and social function significantly deteriorated and more problems with fatigue, dyspnoea, appetite loss and trouble with taste were reported. Recovery occurred by 6 months (except severe fatigue and insomnia in >15% of patients) and maintained at follow-up with no differences between groups. CONCLUSIONS:CRT for localised oesophageal cancer has a significant detrimental impact on many aspects of HRQL; however, recovery is achieved by 6 months and maintained with the exception of persisting problems with severe fatigue and insomnia. The data suggest that the HRQL recovery after definitive CRT is quicker, and there is little lasting deficit compared with treatment including surgery. These data need to be compared with HRQL data from studies evaluating treatments including surgery for oesophageal cancer.

Dataset Information

Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy.

Background

Methods

Results

Conclusions

Publications

Imaging biomarkers of contrast-enhanced computed tomography predict survival in oesophageal cancer after definitive concurrent chemoradiotherapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure